Lupin's Pithampur unit gets Health Canada clearance
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
PITHAMPUR
-
USFDA pulls up Cipla for manufacturing lapses at Pithampur plant
A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed," the USFDA stated in the letter.
-
Cipla's Pithampur unit gets 8 observations from US FDA after inspection
-
USFDA issues 2 observations after inspection of Lupin's Pithampur unit
-
Lupin's Pithampur facilities complete successful MHRA inspection
-
MP cabinet gives nod to policies for startups, tourism
-
Lupin's Goa facility may face regulatory action, says USFDA
-
Lupin’s Pithampur Unit-3 (Indore) receives EIR from USFDA
-
Lupin gets EIR from USFDA for Pithampur facility unit
-
Unichem gets EIR from USFDA for Pithampur, Roha facilities
Advertisement
More in PITHAMPUR
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
